1. The pathogenic characteristics and ethnic differences of diabetic retinopathy
Medical Journal of Chinese People's Liberation Army 2020;45(6):663-671
Diabetic retinopathy (DR) is one of the most common microangiopathies of diabetes mellitus (DM). It is due to abnormal blood glucose metabolism caused by insufficient insulin secretion or decreased activity. Its pathogenesis is complex, related to multi-gene inheritance and environmental factors. At present, the etiologic study of DR has been gradually deepened at home and abroad, but the epidemiological study of minority DR is lacking. This paper reviews DR's characteristics, ethnic differences and its characteristics in ethnic minority.
2.Pre-column Derivatization RP-HPLC for Simultaneous Determination of 17 Amino Acids in Cynomorii Herba from Different Producing Areas and Its Multivariate Statistical Analysis
Zhi-rong GU ; Zhuan-xia MA ; Tian-xiang MA ; Ri-na SA ; Jie-li LIU ; Guo-tai WU ; Mei QI ; Bin GE
Chinese Journal of Experimental Traditional Medical Formulae 2020;26(10):148-155
Objective::To establish a pre-column derivatization reverse-phase high-performance liquid chromatography (RP-HPLC) method for the simultaneous determination of 17 amino acids in Cynomorii Herba from different producing areas and conduct a multivariate statistical analysis. Method::RP-HPLC with pre-column derivatization was employed, with phenyl isothiocyanate (PITC) as derivatization reagent. Separation was performed on a WondaSil C18-WR column (4.6 mm×150 mm, 5 μm), with 0.05 mol·L-1 sodium acetate solution (pH 6.5) as mobile phase A, and acetonitrile-methanol-water (3∶1∶1) as mobile phase B for gradient elution at a flow rate of 0.8 mL·min-1. The detective wave length was set at 254 nm, and the column temperature was maintained at 35 ℃. Principal component analysis (PCA) and systematic cluster analysis (HCA) models were established for multivariate statistical analysis and quality evaluation. Result::17 Kinds of amino acid were detected in Cynomorii Herba, 7 of which were essential amino acids. The 17 amino acids showed good linearity in respective concentration range,
3.Technical specification for Instructions for Clinical Application of Chinese Patent Medicines in China Association of Chinese Medicine.
Xiao-Meng ZHANG ; Ri-Na SA ; Bing ZHANG ; Dan ZHANG ; Jin-Tao LYU ; Xiao-Jiao DUAN ; Zhi-Jian LIN ; Yu-Bo GUO
China Journal of Chinese Materia Medica 2021;46(17):4563-4568
In order to solve the problems of confusion in clinical medication and imperfect instructions in Chinese patent medicines(CPMs), the Standardization Department of the China Association of Chinese Medicine and Center for Pharmacovigilance and Rational use of Chinese Medicine in Beijing University of Chinese Medicine jointly compiled the Instructions for Clinical Application of Chinese Patent Medicines(CPMs). As the interpretation and supplement of drug instruction information, it aims to guide clinical safety and rational use of CPMs. In addition, the technical specification for clinical application description of CPMs has been formulated, which covers the seven processes of "carding instructions, clinical investigation, data retrieval, data screening, evidence classification, path transformation and writing format". It will enable readers of Instructions for Clinical Application of Chinese Patent Medicines to understand the work behind the compilation.
Beijing
;
China
;
Drugs, Chinese Herbal
;
Medicine, Chinese Traditional
;
Nonprescription Drugs
;
Pharmacovigilance
4.Series of group standards of Technical Specifications for Revision of Safety Information in Marketed Chinese Patent Medicine Instructions.
Bing ZHANG ; Xiao-Meng ZHANG ; Zhi-Jian LIN ; Ri-Na SA ; Jin-Tao LYU ; Hao WU ; Yao-Lei LI ; Hui-Zhe XU ; Zheng-Kai HUANG ; Yu-Bo GUO ; Xiang-Fei SU ; Xiao-Jiao DUAN
China Journal of Chinese Materia Medica 2022;47(2):285-294
Drug instructions,the statutory and technical documents recording effectiveness and safety information,are an important basis for guiding doctors,pharmacists,and patients to use drugs rationally,and their scientificity,standardization,and accuracy directly affect the medication safety of the public. The sections of adverse drug events,contraindications,precautions,warnings,and application for specific populations in drug instructions directly express safety information and measures for rational use of drugs. In the drug life cycle,marketing authorization holders( MAHs) need to update safety information in the instructions promptly to ensure the safety and effectiveness of clinical drug medication. At present,revising instructions is an important measure to control drug risks. In the drug life cycle,in order to standardize the revision of safety information in the instructions by MAHs and eliminate inexact terms such as " unclear",the Technical Specifications for Revision of Safety Information in Marketed Chinese Patent Medicine Instructions,a series of group standards,have been established under the guidance of Standardization Department,China Association of Chinese Medicine. Therefore,on the basis of the existing rules and regulations,the standardized technical procedures for revising instructions came into being to help clinical safe and rational medication of drugs,and implement the strategy of " Healthy China".
China
;
Drug-Related Side Effects and Adverse Reactions
;
Drugs, Chinese Herbal/adverse effects*
;
Humans
;
Medicine, Chinese Traditional
;
Nonprescription Drugs/adverse effects*
;
Reference Standards
5.Interpretation of Technical Specifications for Revision of Safety Information in Marketed Chinese Patent Medicine Instructions.
Xiao-Meng ZHANG ; Zhi-Jian LIN ; Bing ZHANG ; Ri-Na SA ; Jin-Tao LYU ; Hao WU ; Yao-Lei LI ; Hui-Zhe XU ; Zheng-Kai HUANG ; Yu-Bo GUO ; Xiang-Fei SU ; Xiao-Jiao DUAN
China Journal of Chinese Materia Medica 2022;47(2):295-300
Technical Specifications for Revision of Safety Information in Marketed Chinese Patent Medicine Instructions,a series of group standards,were proposed by Professor ZHANG Bing from Research Center for Pharmacovigilance and Rational Use of Traditional Chinese Medicine,and underwent centralized management by Chinese Association of Chinese Medicine. They were officially released on July 23 and implemented on July 31,2021. The series of group standards consist of six sections,including general principles,adverse drug events,contraindications,precautions,application for special populations,and warnings. The section of general principles is comprised of holistic and programmatic expressions,which explain the general technical requirements for revising the marketed Chinese patent medicine instructions. The other five sections focus on information collection,screening,transformation,and illustration of specific items,forming a standardized revision technical process. This series of standards is the result of multiple rounds of research and the suggestions of more than 200 experts in different professional fields of " medicine-pharmacy-management-law-enterprise" have been gathered therein to reach a consensus. With the purposes of establishing standardized technical specifications for the revision of safety information in the marketed Chinese patent medicine instructions,guiding marketing authorization holders in revising the instructions,filling the gaps in the research of Chinese patent medicine instructions,promoting the deve-lopment of pharmaceutical care and academic research,and encouraging the rational and safe medication of Chinese patent medicine,the series of group standards is of great significance.
China
;
Drug-Related Side Effects and Adverse Reactions
;
Drugs, Chinese Herbal/adverse effects*
;
Humans
;
Medicine, Chinese Traditional
;
Nonprescription Drugs/adverse effects*
;
Pharmacovigilance